Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue

Vincent Vander Poorten(KU Leuven), Pierre Delaere, Jeroen Meulemans(KU Leuven), Esther Hauben(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Sandra Nuyts(Cancer Institute (WIA)), Robert Hermans(Universitair Ziekenhuis Leuven)

World Journal of Surgical Oncology

July 15, 2015

10.1186/s12957-015-0630-6

Cited by 24

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma

|New England Journal of Medicine|2017|994

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

|Journal of Clinical Oncology|2009|573

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

|The Lancet Oncology|2016|504

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

|Journal of Clinical Oncology|2010|445

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

|The Lancet|2017|401